Evaluating the Real-life Effect of MP-AzeFlu on Asthma Outcomes in Patients with Allergic Rhinitis and Asthma in UK Primary Care

Overview

Journal World Allergy Organ J

Specialty Allergy & Immunology

Date 2020 Dec 30

PMID 33376573

Citations 3

Authors

Hilda J I de Jong

Jaco Voorham

Glenis K Scadding

Claus Bachert

Giorgio Walter Canonica

Peter Smith

Ulrich Wahn

Dermot Ryan

Jose A Castillo

Victoria A Carter

Ruth B Murray

David B Price

Affiliations

Soon will be listed here.

Abstract

Background: MP-AzeFlu (Dymista®; spray of azelastine/fluticasone propionate) is the most effective allergic rhinitis (AR) treatment available. Its effect on asthma outcomes in patients with AR and asthma is unknown.

Methods: This pre-post historical cohort study, using the Optimum Patient Care Research Database, included patients aged ≥12 years, from UK general practice with active asthma (defined as a recorded diagnosis, with ≥1 prescription for reliever or controller inhaler) in the year before or at the initiation date. The primary study outcome was change in number of acute respiratory events (i.e. exacerbation or antibiotic course for a respiratory event) between baseline and outcome years. The effect size of MP-AzeFlu was quantified as the difference in % of patients that improved and worsened.

Results: Of the 1,188 patients with AR and asthma included, many had a record of irreversible obstruction (67%), and uncontrolled asthma (70.4%), despite high mean daily doses of reliever/controller therapy and acute oral corticosteroid use, in the year pre-MP-AzeFlu initiation. MP-AzeFlu initiation was associated with fewer acute respiratory events (effect size (e) = 5.8%, p = 0.0129) and a reduction in daily use of short-acting β-agonists, with fewer patients requiring >2 SABA puffs/week (e = 7.7% p < 0.0001). More patients had well-controlled asthma 1-year post-MP-AzeFlu initiation (e = 4.1%; p = 0.0037), despite a reduction in inhaled corticosteroids (e = 4.8%; p = 0.0078).

Conclusions: This study provides the first direct evidence of the beneficial effect of MP-AzeFlu on asthma outcomes in co-morbid patients in primary care in the United Kingdom.

Trial Registration: EUPAS30940. Registered August 13, 2019.

Citing Articles

Allergic rhinitis management: a Delphi Consensus promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP).

Miraglia Del Giudice M, Marseglia G, Peroni D, Zicari A, Dinardo G, Ciprandi G Ital J Pediatr. 2024; 50(1):254.

PMID: 39609911 PMC: 11603965. DOI: 10.1186/s13052-024-01824-5.

The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review.

Tantilipikorn P, Kirtsreesakul V, Bunnag C, Vangveeravong M, Thanaviratananich S, Chusakul S J Asthma Allergy. 2024; 17:667-679.

PMID: 39045291 PMC: 11264124. DOI: 10.2147/JAA.S451733.

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.

Ramphul M, Lo D, Gaillard E J Asthma Allergy. 2021; 14:525-538.

PMID: 34045872 PMC: 8144021. DOI: 10.2147/JAA.S265657.

References

Brescia G, Parrino D, Zanotti C, Tealdo G, Barion U, Sfriso P . Blood Eosinophil and Basophil Values Before and After Surgery for Eosinophilic-type Sinonasal Polyps. Am J Rhinol Allergy. 2018; 32(3):194-201. DOI: 10.1177/1945892418768590. View

Feng C, Miller M, Simon R . The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012; 26(3):187-90. PMC: 3906509. DOI: 10.2500/ajra.2012.26.3762. View

Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M . Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004; 113(1):86-93. DOI: 10.1016/j.jaci.2003.10.010. View

Kortekaas Krohn I, Callebaut I, Alpizar Y, Steelant B, Van Gerven L, Skov P . MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2017; 73(5):1084-1093. DOI: 10.1111/all.13349. View

Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica G . Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4):369-77. DOI: 10.1159/000351404. View

Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee A . Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J. 2010; 19(3):266-73. PMC: 6602242. DOI: 10.4104/pcrj.2010.00040. View

Price D, Swern A, Tozzi C, Philip G, Polos P . Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy. 2006; 61(6):737-42. DOI: 10.1111/j.1398-9995.2006.01007.x. View

Grossman J . One airway, one disease. Chest. 1997; 111(2 Suppl):11S-16S. DOI: 10.1378/chest.111.2_supplement.11s. View

Price D, Smith P, Hellings P, Papadopoulos N, Fokkens W, Muraro A . Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol. 2015; 11(11):1205-17. DOI: 10.1586/1744666X.2015.1081814. View

10.

Roca-Ferrer J, Pujols L, Perez-Gonzalez M, Alobid I, Callejas B, Vicens-Artes S . Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy Asthma Clin Immunol. 2018; 14:86. PMC: 6299636. DOI: 10.1186/s13223-018-0311-4. View

11.

Reddel H, Taylor D, Bateman E, Boulet L, Boushey H, Busse W . An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180(1):59-99. DOI: 10.1164/rccm.200801-060ST. View

12.

Clatworthy J, Price D, Ryan D, Haughney J, Horne R . The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009; 18(4):300-5. PMC: 6619365. DOI: 10.4104/pcrj.2009.00037. View

13.

Nathan R, Yancey S, Waitkus-Edwards K, Prillaman B, Stauffer J, Philpot E . Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005; 128(4):1910-20. DOI: 10.1378/chest.128.4.1910. View

14.

Berger W, Bousquet J, Fox A, Just J, Muraro A, Nieto A . MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016; 71(8):1219-22. PMC: 5089625. DOI: 10.1111/all.12903. View

15.

Foresi A . A comparison of the clinical efficacy and safety of intranasal fluticasone propionate and antihistamines in the treatment of rhinitis. Allergy. 2000; 55 Suppl 62:12-4. DOI: 10.1034/j.1398-9995.2000.055suppl62012.x. View

16.

Bousquet J, Meltzer E, Couroux P, Koltun A, Kopietz F, Munzel U . Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018; 6(5):1726-1732.e6. DOI: 10.1016/j.jaip.2018.01.031. View

17.

Cingi C, Gevaert P, Mosges R, Rondon C, Hox V, Rudenko M . Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017; 7:17. PMC: 5452333. DOI: 10.1186/s13601-017-0153-z. View

18.

Neslusan C, Crown W, Torres A . Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002; 109(1):57-62. DOI: 10.1067/mai.2002.120554. View

19.

Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Togias A . Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160. DOI: 10.1111/j.1398-9995.2007.01620.x. View

20.

Costa D, Amouyal M, Lambert P, Ryan D, Schunemann H, Daures J . How representative are clinical study patients with allergic rhinitis in primary care?. J Allergy Clin Immunol. 2011; 127(4):920-6.e1. DOI: 10.1016/j.jaci.2010.10.058. View